Shire Named One of Americas Most Reputable Companies by Reputation Institute
Shire has been named the #1 most reputable healthcare company in the US, and 31st most reputable company overall in the US, according to the 2015 US RepTrak 100 list released by Reputation Institute and published in Forbes magazine.
The US RepTrak rankings measure the public’s perception of companies based on seven dimensions: innovation, leadership, governance, citizenship, workplace, financial performance, and products/services.
“This is the first time we’ve been included in the US RepTrak 100 and we are extremely proud to have ranked so highly given this is a reflection of how the public views our company," said Shire CEO Flemming Ornskov.
“Patients are the heart of Shire and we work hard and with urgency every day, all over the world, to earn and keep their trust. While we will never be complacent, it is reassuring to see that we are making progress through our focus on leadership, responsibility and innovation.”
Reputation Institute’s RepTrak provides a measurement of how the public views the world’s best-known companies. The RepTrak database is normative, examining 15 stakeholder groups in more than 25 industries and more than 50 countries for more than 7000 companies. The 2015 US RepTrak 100 examines perceptions of companies by the US general public based on over 70,000 interviews.
“The top US companies proactively manage their reputations by investing as much in corporate dimensions like governance, citizenship and workplace as they do in their products and services,” says Brad Hecht, Chief Research Officer at Reputation Institute.
“Companies with strong reputations are 15 times more likely to attract better talent and they reap significant financial benefits, too. The most reputable companies see a stock performance that is 2 times better than the overall market and they benefit from a 6.5% increase in recommendations every time they improve their RepTrak score by 5 points,” he concluded.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.